Latest News-CliniExpert

FDA Approves Updated Aduhelm Prescribing Information to Emphasize Population Studied in Clinical Trials

Aduhelm should be initiated in patients with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s dementia CAMBRIDGE, Mass. and TOKYO, July 08, 2021 (GLOBE NEWSWIRE) -- Biogen (Nas

Try the best and demand every team member as the one who Keeps His Word. - James Ho

China Industrial Economy News reporter Linlin Zhao -- Over the past 40 years of reform and opening up, the ranks of small and medium-sized enterprises have become larger and larger, and they have beco

Merck Provides Update on Keytruda (pembrolizumab) Indication in Third-Line Gastric Cancer in the US

KENILWORTH, N.J.--(BUSINESS WIRE) July 1, 2021 -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the company plans to voluntarily withdraw the U.S. accelera

James Ho, Founder of The CliniExpert Answered Questions of Reportes

Q：Would you give us a brief about CliniExpert? James Ho：Based in China, we are offering services to the global pharmaceutical research industry, esp. for the supply of the investigational product. We

In the "post-epidemic" era, How Can Chinese Clinical Comparators Save Your Cost ？

What is the "post-epidemic" era? My colleague Mr.Zhang once used to having noodles for lunch in the restaurant which is near the company for several years. But in 2020, this restaurant was c

First COVID-19 Variant Vaccine AZD2816 Phase II/III Trial Participants Vaccinated

27 June 2021 -- The first participants in a Phase II/III trial for the new COVID-19 variant vaccine AZD2816 were vaccinated today to assess its safety and immunogenicity in both previously vaccinated

FDA Approves Kerendia (finerenone) for the Treatment of Patients with Chronic Kidney Disease Associated with Type 2 Diabetes

WHIPPANY, N.J.-- July 9, 2021 (BUSINESS WIRE) -- Bayer announced today the United States (U.S.) Food and Drug Administration (FDA) has approved Kerendia (finerenone), a first-in-class nonsteroidal min

Positive New Data for Johnson & Johnson Single-Shot COVID-19 Vaccine on Activity Against Delta Variant and Long-lasting Durability of Response

NEW BRUNSWICK, N.J., July 1, 2021 -- Johnson & Johnson (NYSE: JNJ) (the Company) today announced data that demonstrated its single-shot COVID-19 vaccine generated strong, persistent activity again

Novavax Publishes Results of United Kingdom Phase 3 Clinical Trial in New England Journal of Medicine, Demonstrating High Levels of Efficacy of COVID-19 Vaccine

GAITHERSBURG, Md., June 30, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the publicat

Vaxzevria Induced Immunity for at Least One Year Following a Single Dose and Strong Immune Responses Following Either a Late Second Dose or a Third Dose

28 June 2021 -- A sub-analysis from the Oxford-led COV001 and COV002 trials with Vaxzevria induced strong immune responses following either a prolonged second dose interval of up to 45 weeks or follow

Nirsevimab MEDLEY Phase II/III Trial Demonstrated Favourable Safety and Tolerability Profile in Infants at High Risk of RSV

28 June 2021 -- The MEDLEY Phase II/III trial evaluated the safety and tolerability of nirsevimab compared to Synagis (palivizumab) when given to infants at high risk of respiratory syncytial virus (R

FDA Approves Rylaze for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

DUBLIN, June 30, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the U.S. Food and Drug Administration (FDA) approval of Rylaze (asparaginase erwinia chrysanthemi (recombi